Immix Biopharma, Inc. (IMMX)
9.345
+0.06
(+0.59%)
USD |
NASDAQ |
Oct 09, 10:31
Immix Biopharma Net Income (Quarterly) : -11.56M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -11.56M |
| March 31, 2026 | -10.09M |
| December 31, 2025 | -10.69M |
| September 30, 2025 | -7.586M |
| June 30, 2025 | -6.623M |
| March 31, 2025 | -4.542M |
| December 31, 2024 | -4.812M |
| September 30, 2024 | -7.149M |
| June 30, 2024 | -4.406M |
| March 31, 2024 | -5.331M |
| December 31, 2023 | -5.155M |
| Date | Value |
|---|---|
| September 30, 2023 | -4.344M |
| June 30, 2023 | -3.598M |
| March 31, 2023 | -2.498M |
| December 31, 2022 | -3.800M |
| September 30, 2022 | -1.535M |
| June 30, 2022 | -1.563M |
| March 31, 2022 | -1.332M |
| December 31, 2021 | -22.76M |
| September 30, 2021 | -0.4033M |
| March 31, 2021 | -1.017M |
| September 30, 2020 | -0.1163M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Atossa Therapeutics, Inc. | -8.491M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 11.56M |
| EPS Diluted (Quarterly) | -0.1812 |
| Enterprise Value | 433.46M |
| Earnings Yield | -9.42% |
| Normalized Earnings Yield | -9.419 |